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4Summary
Perceived health status (HS) and quality of life (QoL) are regularly used as outcome variables 
to evaluate the effect of various treatments for patients with chronic obstructive pulmonary 
disease (COPD). Disease-specific HS questionnaires for patients with COPD quantify the 
impact of disease on patients’ daily life, health and well-being, and they usually include items 
that address both physical and psychological aspects. Application of the term quality of life 
often seems to be inconsistent, but there is some consensus that QoL should probably be 
reserved for scales where the items refer to life experiences but not in the context of disease. 
QoL is a broader concept than HS and includes factors such as social and psychological well-
being and satisfaction with life, factors that may or may not be influenced by health or 
treatment. Factors that are closely related to health conditions – easily captured by disease-
specific instruments – do not necessarily affect general QoL very much. Conversely, factors 
that are not health-related, and thus missed by disease-specific instruments, can make a 
significant difference in the assessment of general QoL.  
The first aim of the thesis was to examine the associations between HS, QoL and physical 
function among COPD patients. Our results indicated that in order to achieve a 
comprehensive assessment, both total scores and subscores of HS and QoL instruments 
should be included to evaluate the impact of COPD on a person’s life and to measure the 
effects of pulmonary rehabilitation. Furthermore, it can be important to distinguish between 
variables related to physical functioning and variables related to psychological well-being. 
COPD can have a substantial effect on the physical, emotional and social aspects of patients’ 
lives. Activities of daily living are often considerably impeded and many COPD patients 
suffer from emotional problems such as anxiety and depression. HS instruments, QoL 
instruments and physical indicators – e.g. spirometric values or walking tests – can show how 
patients’ lives are affected by COPD. Furthermore, they can be useful in order to evaluate 
effects of a pulmonary rehabilitation programme (PRP). Beneficial outcomes of PRPs are well 
documented and previous research has indicated that rehabilitation can enhance patients’ 
exercise capacity, HS, QoL and well-being. The magnitude of improvements, however, has 
varied considerably, both for physical tests and self-reported outcome variables. Also, 
5improvements in emotional well-being and QoL have tended to be weaker and less consistent 
than improvements in HS.  
The second aim of the thesis was to assess short-term and longitudinal changes in HS and 
QoL after a pulmonary rehabilitation programme for a sample of female and male COPD 
patients, as compared to a sample of asthma patients referred to the same PRP. 
A short inpatient PRP was followed by immediate positive changes on HS, QoL and exercise 
capacity for the sample of COPD patients. Significant improvements were observed for 
variables related to physical functioning; emotionally related variables changed considerably 
less, although in a positive direction. Surprisingly, changes in exercise capacity did not co-
vary with changes in physically related HS or QoL variables. The PRP appeared to have 
similar effects for female and male COPD patients. In contrast to an asthma sample, however, 
most of the gains in HS and QoL for the COPD sample had vanished at six months follow-up.   
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7Most important abbreviations 
COPD = Chronic obstructive pulmonary disease 
HS = Health status 
QoL = Quality of life 
PRP = Pulmonary rehabilitation programme 
PCA = Principal component analysis 
ES = Effect size 
ANOVA = Analysis of variance 
ANCOVA = Analysis of covariance 
6MWD = Six minutes walking distance (in meters) 
6MWD % = Six minutes walking distance; presented as percent of expected values, adjusted 
for age, gender, weight and height
FEV1 = Forced expiratory volume in 1 second (in litres) 
FEV1 % = Forced expiratory volume in 1 second; presented as percent of expected values, 
adjusted for age, gender and height.
BPQ = The Breathing Problems Questionnaire (10 items short version) 
PQoL = The Perceived Quality of Life Scale 
STAI = Spielberger’s State and Trait Anxiety Inventory 
SGRQ =  The St George Respiratory Questionnaire
QOLS = The Quality of Life Scale 
5PF = Five Personality Factors
8Introduction 
   
Perceived health status (HS) and quality of life (QoL) are regularly used outcome variables to 
evaluate the effect of various treatments for patients with chronic obstructive pulmonary 
disease (COPD). Although there is no consensus, the terms HS and health-related quality of 
life (HRQoL) are commonly used for scales where the items refer to the impact of disease on 
various experiences (1-5). Application of the term quality of life (QOL) often seems to be 
inconsistent, but there is some consensus that QoL should probably be reserved for scales 
where the items refer to life experiences but not in the context of disease. QoL is a broader 
concept than HS and includes factors such as social and psychological well-being and 
satisfaction with life (6), factors that may or may not be influenced by health or treatment. 
Factors that are closely related to health conditions – easily captured by disease-specific 
instruments – do not necessarily affect general QoL very much. Conversely, factors that are 
not health-related, and thus missed by disease-specific instruments, can make a significant 
difference in the assessment of general QoL.
Disease-specific HS questionnaires for patients with COPD quantify the impact of disease on 
patients’ daily life, health and well-being (5), and they usually include items that address both 
physical and psychological aspects. Curtis et al (3) define health status as “the impact of 
health on a person’s ability to perform and derive fulfilment from the activities of daily life”, 
and they claim that a patient’s self-reported HS should include both health-related quality of 
life (HRQoL) and functional status. In other words, a HS instrument should invite the patients 
to report how their disease influences what they are able to do and how they feel in daily life. 
The short version of the Breathing Problems Questionnaire (7) (called BPQ throughout the 
thesis) satisfies these criteria, and its ten items cover a relatively broad range of activities and 
perceptions of well-being in everyday life.
9In the COPD literature, relatively low associations between self-reported HS and measures of 
lung function are often reported (8-10). One explanation for the low associations between HS 
questionnaires and lung function could be that only total scores on the HS instrument are 
used. If the BPQ really captures the two mentioned aspects: functional status and HRQoL, 
then these two parts of the instrument should be differentially related to other variables. One 
would expect the functional status part of the instrument to be largely associated with physical 
performance tests, but less associated with psychological factors. The HRQoL part of the 
instrument, in contrast, is hypothesized to correlate strongly with variables that measure 
general quality of life and psychological well-being , while the associations with physical 
performance tests should be considerably lower (11-13). The analyses in paper 1 were 
conducted to investigate whether the short version BPQ can be used to measure not only self-
reported HS as a whole, but also the two subdimensions hypothesised by Curtis et al. 
Previously it was shown that the 33 items of the full version BPQ tended to cluster around 
two such dimensions – “functional problems” and “negative evaluations” (4). The 10 items 
version, however, had not been validated for that purpose; hence an additional feature of 
paper 1 was to demonstrate that this two-dimensional solution applies to the shorter version 
too.
For COPD patients, measures of disease-specific HS (hereafter we use the term HS to include 
HRQoL) can be more or less correlated with measures of general QoL, since HS scales are 
multi-component, and each component may have a different relationship with QoL. 
Furthermore, HS and QoL measures can be more or less correlated with measures of disease 
severity, such as lung function or exercise capacity. Engstrøm et al (14) found that 
physiological, functional and psychosocial consequences of COPD was only moderately 
related to each other. They concluded that the impact of COPD is best assessed by a battery of 
instruments that not only tap disease-specific effects, but also the burden on daily functioning 
and emotional well-being. Sturesson and Branholm (15) discovered that in a group of COPD 
patients, satisfaction with life as a whole was unrelated to lung function but significantly 
associated with two subscores (emotional function and fatigue) of a disease-specific HS 
instrument. Fuchs-Climent et al (16) observed that generic QoL was independent of disease 
severity among COPD patients, which further emphasized the value of different types of 
evaluation. Results such as these indicate that it can be useful to distinguish between quality 
of life, health status and disease severity. In paper 2, we therefore investigated associations 
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between two measures of self-reported QoL, two measures of self-reported HS plus clinical 
variables and neuroticism in a sample of COPD patients. Our aim was to investigate to what 
extent it is meaningful to discriminate QoL from the different components of HS. 
COPD can have a substantial effect on the physical, emotional and social aspects of patients’ 
lives (17). Activities of daily living are often considerably impeded (18) and many COPD 
patients suffer from emotional problems such as anxiety and depression (19). HS instruments, 
QoL instruments and physical indicators – e.g. spirometric values or walking tests – can show 
how patients’ lives are affected by COPD. Furthermore, they are useful to evaluate effects of 
pulmonary rehabilitation programs (PRPs). Beneficial outcomes of PRPs are well documented 
(20-23), and previous research has indicated that pulmonary rehabilitation can enhance 
patients’ exercise capacity, HS, QoL and well-being (24-30). The magnitude of 
improvements, however, has varied considerably, both for physical tests and self-reported 
outcome variables. Also, improvements in emotional well-being and QoL have tended to be 
weaker and less consistent than improvements in HS (31-35).  
In paper 3, we assessed a sample of COPD patients on a set of outcome variables before and 
after a 4 weeks inpatient PRP. The first aim of our study was to assess whether physically 
related variables would improve more than emotionally related variables, since the 
rehabilitation program had a main focus on physical exercise. Since COPD is a chronic 
disease, we did not expect statistically significant changes in lung function for the sample. 
However, if the PRP had a positive effect, we expected that exercise capacity (walking 
distance) and physically oriented questionnaire scores would improve considerably. We also 
expected that emotionally oriented questionnaire scores such as emotional HS, general QoL 
and trait anxiety would improve, but to a smaller degree.  
Few studies have investigated whether change in one outcome variable correlates with change 
in another outcome variable. The second aim of our study was therefore to assess the relations 
between changes in different types of outcome variables. Our main expectation was that 
changes in exercise capacity would be at least moderately related to changes in perceived HS 
and/or QoL – particularly to physically related subscores. 
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COPD represents a growing health problem among women (36;37). Whether women are more 
susceptible than men to development of this disease remains controversial (38-40), but results 
have indicated that physicians under-diagnose COPD in females (41) and a recent study 
suggested that women with COPD develop symptoms that reduce perceived health status at a 
younger age than men (42). Also, it has been shown that with equal predicted lung function 
values, female COPD patients tend to have lower exercise capacity and worse HS scores than 
their male counterparts (43). In other words, there may be gender differences in the clinical 
manifestations of this disease.  
A recent review (44) stated that the impact of COPD in women is significantly understudied, 
and it was speculated that female and male COPD patients may show different responses to 
various forms of treatment. Therefore, in paper 4, we addressed two central research 
questions: Did the four weeks PRP have different effects for men and women? Were there any 
differences between female and male COPD patients referred to an inpatient PRP? HS, QoL, 
anxiety, lung function and exercise capacity were compared cross-sectionally and 
longitudinally. Additionally, we analyzed associations between different outcome measures, 
which could be important for the interpretation of eventual gender differences. 
Several studies have addressed the questions of short-term versus long-term effects of PRP 
(27;28;34;45-56). The majority of PRP studies, however, have been conducted for samples of 
patients with COPD, and only a few reports have used asthma samples (57) or combined 
samples of COPD and asthma patients (47;58). Therefore, although both these diagnoses 
represent obstructive lung disease, it is still an open question whether patients in the two 
groups react similarly to PRPs on an immediate or long-term basis. In paper 5, we compared 
the short and long-term changes in HS, QoL and anxiety scores for COPD patients versus 
asthma patients. This was the main purpose of the study.  
To summarize, there were two main aims of this thesis: The first aim was to examine closer 
the relations between HS, QoL and physical function among COPD patients. Secondly, we 
wanted to assess short-term and longitudinal changes in HS and QoL after a short inpatient 
PRP for a sample of female and male COPD patients, as compared to a sample of asthma 
patients referred to the same PRP. 
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Subjects and Methods 
All papers include lung patients referred to a 4 weeks inpatient pulmonary rehabilitation 
programme (PRP) at a small hospital in the south-east of Norway.
Two separate samples/studies 
The thesis is based on data from two different samples of patients.
The first sample provided the data for papers 1 and 2. This was a cross-sectional study, in 
which a sample of COPD patients was assessed on several variables once; immediately before 
the start of a rehabilitation programme.
The second sample – a combined sample of COPD and asthma patients – was assessed 
immediately before and after the rehabilitation programme and at follow-up six months later. 
Data from this longitudinal study were analysed in papers 3 – 5. Since the main focus of the 
thesis is COPD, results for asthma patients are represented only in one paper (paper 5), in 
order to illustrate longitudinal differences between COPD and asthma patients after a PRP. 
Due to different degrees of completion of tests and questionnaires, N will vary between 
different analyses conducted on the same sample. 
Ethics
All patients in both samples were informed that participation in the research projects was 
voluntary and that information would be treated confidentially. Those who wanted to 
participate gave their written consent.  
The regional ethical committee had approved both studies in advance. 
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Rehabilitation programme 
Patients participated in a four weeks inpatient, multidisciplinary PRP. All patients were 
exposed to the same 4 weeks activity plan, which comprised physical exercise, educational 
lectures, lifestyle change support and social sharing with other COPD patients. The 
programme consisted of three to four 45 min educational or exercise group sessions all 
weekdays. Physical exercise was conducted individually and in groups; outdoors, in a 
gymnasium and in a warm swimming pool. Educational lectures were given by physicians, 
nurses, physiotherapists, psychologists, occupational workers and social workers. The lectures 
covered topics such as: Causes, mechanisms and treatment of COPD, living with chronic 
disease, optimal physical exercise and social rights for pulmonary patients. Patients were seen 
at least weekly by their attending physician, and issues such as medication or nutrition were 
followed up regularly by nurses. All patients were given individual appointments with 
physiotherapist. Individual appointments with social worker or psychologist were given as 
needed. While still at the hospital, patients were encouraged to continue with physical 
exercise after discharge, but no maintenance program was applied in the follow-up period six 
months after discharge.
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Sample 1 
9 COPD patients
9 Asked for participation: N = 160 
Did not want to participate: N = 40 
Reduced vision prevented tests: N = 2 
9 Enrolled in the study: COPD patients: N = 118 
Excluded due to change of diagnosis during the stay at the hospital: N = 8 
9 COPD patients with diagnosis confirmed: N = 110 
Reduced N due to insufficient completion of tests and questionnaires lead to: 
Paper 1 
A total of N = 97 were suitable for most data analyses
9 N = 93 in the analyses entailing 6MWD
Paper 2 
A total of N = 105 were suitable for most data analyses
9 N = 102 in the analyses entailing 5PF 
9 N = 90 in the analyses entailing SGRQ
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Sample 2 
9 COPD and asthma patients 
9 Asked for participation: N = 354; COPD (N = 249), asthma (N = 105). 
Did not return envelopes: N = 133 
9 Enrolled in the study: N = 221; COPD (N = 155) and asthma (N = 66) patients. 
COPD patients: 
Enrolled: N = 155
Completed questionnaires at t1; 2 weeks before the PRP: N = 155 
Completed questionnaires at t2; 2 weeks after the PRP: N = 110  
Completed questionnaires at t3; 6 months after the PRP: N = 96 
Performed walking test at T1; first week of the PRP: N = 118 
Performed walking test at T2; last week of the PRP: N = 104 
Completed questionnaires at t1, t2 and also walking tests at T1 and T2: N = 95 
Completed questionnaires at t1, t2, t3 and also walking tests at T1 and T2: N = 81 
Asthma patients: 
Enrolled: N = 66 
Completed questionnaires at t1; 2 weeks before the PRP: N = 66 
Completed questionnaires at t2; 2 weeks after the PRP: N = 45 
Completed questionnaires at t3; 6 months after the PRP: N = 40 
Performed walking test at T1; first week of the PRP: N = 39 
Performed walking test at T2; last week of the PRP: N = 33 
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N was reduced due to drop-out, change of diagnosis during the PRP or insufficient 
completion of tests and questionnaires at different point in time. This provided the 
following sample sizes for the papers: 
Paper 3 
9 COPD patients only; measured before and immediately after the PRP. N = 95 were 
considered suitable for data analyses; only patients with all actual variables (lung 
function, walking tests and questionnaires) measured immediately pre and post 
rehabilitation intact were included in these analyses. 
Of these 95, N = 3 were excluded due to change of diagnosis during the PRP 
N = 92 COPD patients analysed 
Paper 4 
9 COPD patients only, questionnaires completed at all points in time (t1 – t3), N = 96. 
For walking tests (T1 and T2), N = 81. 
Excluded N = 4 due to change of diagnosis during the PRP 
N = 92 patients – 46 females and 46 males – included in the data analyses. 
Paper 5 
9 COPD and asthma patients, measured at all points in time (t1 – t3): N = 136 
Excluded N = 4 due to change of diagnosis during the PRP 
N = 132 patients (COPD N = 92, asthma N = 40) included in the data analyses. 
Please notice that the samples in papers 3 and 4 are not identical. 
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The five papers; subjects and methods 
Paper 1 
Analyses in paper 1 were conducted on a sample of 97 COPD patients. First, we used a 
principal component analysis (PCA) to examine the internal structure of the BPQ. Then, 
based on the results of the PCA, we constructed two subscores of the BPQ. Finally, we 
correlated the BPQ total scores and subscores to a set of other variables; personality traits, 
general perceived quality of life, happiness, exercise capacity and lung function.
Perceived health status (HS) was measured by the short version of the Breathing Problems 
Questionnaire (7). The BPQ short version was developed as a purpose-specific and disease-
specific instrument for measuring changes in perceived health status among COPD patients. It 
has10 items, each with a scoring range 0 – 3, which can be added to a total score that ranges 
from 0 to 30. Higher BPQ scores mean worse health status. 
Perceived quality of life (QoL) and happiness were measured by the Perceived Quality of Life 
Scale (59), which measures people’s satisfaction with life over several different domains. 
QoL was calculated as the mean of the first 19 items of the PQoL, in which the participants 
rate their satisfaction on an 11-point end-anchored scale from 0 (“extremely dissatisfied”) to 
10 (“extremely satisfied”). (Higher PQoL scores mean better quality of life.) Happiness was 
measured by one item (PQoL20) that measures happiness (“How happy are you?”) on an 11-
point scale from 0 (“extremely unhappy”) to 10 (“extremely happy”).  
Personality traits were measured by the Five Factor Model of personality by 20 selected 
adjective scales from 5PFa (60). The five factors are: Surgency, agreeableness, 
conscientiousness, emotional stability/neuroticism and openness to experience.
Exercise capacity was measured by 6-minute walking tests (6MWD) according to ATS 
guidelines (61). All tests were conducted indoors, along flat, straight corridors with 30 meters 
marked walking courses. Patients were instructed to walk as far as possible for 6 minutes, but 
permitted to slow down, to stop, and to rest as necessary. 
Lung function was measured as forced expiratory volume in 1 s (FEV1) recorded from the 
better of two flow-volume curves (Jaeger, Masterlab) and presented as percent of expected 
values, adjusted for age, gender and height (FEV1 %) (62).
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Paper 2 
Analyses in paper 2 were conducted on a sample of 105 COPD patients.  
First, we calculated correlation coefficients and ran a PCA in order to investigate associations 
between two instruments measuring disease-specific HS, two instruments measuring general 
QoL, personality trait emotional stability/neuroticism, exercise capacity and lung function.  
HS was measured by two disease-specific questionnaires; the short version of the BPQ and 
the St George Respiratory Questionnaire (SGRQ).
In addition to the total score of the BPQ, a BPQ physical subscore (BPQ phys) was calculated 
by adding items 1 – 4 and a BPQ emotional subscore (BPQ emo) was calculated by adding 
items 7 – 10. The SGRQ is a 76-item questionnaire for self-completion (63). Responses are 
given partly on scales, partly as “right”/”wrong”. The SGRQ gives a total score (SGRQ tot) as 
well as sub-scores for the degree of respiratory symptoms (SGRQ symp), the level of activity 
restriction (SGRQ act) and the impact of the pulmonary disease (SGRQ imp).  For both 
instruments, higher scores mean worse health status. 
Qol was measured by the PQoL and the Quality of Life Scale (QOLS) (64;65); only total 
scores were used for these instruments.  
Personality trait emotional stability/neuroticism, exercise capacity and lung function were 
measured as in paper 1.  
19
Paper 3 
In paper 3, a sample of 92 COPD patients was assessed on a set of different questionnaire-
based indicators immediately before and after the 4 weeks pulmonary rehabilitation 
programme. We measured disease-specific HS, general perceived QoL and trait anxiety.
HS was measured by the BPQ; both the total score and the two subscores emotional HS and 
physical HS were included in the analyses.
QoL was measured by the PQoL; in addition to total scores two subscores were included in 
the analyses; a physical score (PQoL phys) and a social score (PQoL social).
Anxiety was measured by the trait part of Spielberger’s state/trait anxiety inventory (STAI) 
(66). The scale consists of 20 questions, each with a scoring range 1 – 4, some of them in 
reversed order, which can be added to calculate a trait anxiety total score that ranges from 20 
to 80.
Exercise capacity and lung function were measured at the start and near the end of the 
rehabilitation programme, by the same methods as in papers 1 and 2. 
T-tests for paired samples were used to analyze changes in scores over time. To evaluate the 
magnitude of changes from before to after the PRP, Cohen’s d was used as an estimate of 
effect size (ES). It was calculated by dividing the mean change score for a variable with the 
pooled standard deviation of raw scores on the same variable, from before to after 
rehabilitation. Values of d were interpreted as follows: d < 0.2 = small effects, 0.2  d < 0.5 = 
medium effects, d  0.5 = large effects. For the purpose of analyzing associations between 
variable changes, we did as follows. Using the criterion of change in walking tests 
(ǻ6MWD), patients were allocated into one of three groups: Group 1 = worsening or no 
improvement (ǻ6MWD  0 meters), N = 29; Group 2 = small or moderate improvement (0 
meters < ǻ6MWD  40 meters), N = 32; Group 3 = large improvement (ǻ6MWD > 40 
meters), N = 31. Then, these three groups of patients were tested for changes over time on 
other variables by repeated measures ANCOVAs. Age and gender were used as covariates in 
these analyses. 
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Paper 4 
A sample of 92 COPD patients – 46 females and 46 males – was assessed on a set of different 
questionnaire-based indicators immediately before and after the 4 weeks pulmonary 
rehabilitation programme and at six months follow-up. (As noted earlier, this sample was not 
identical to the sample in paper 3, although there was considerable overlap.)
As in paper 3, we measured total scores and subscores of disease-specific HS and general 
perceived QoL plus trait anxiety. Exercise capacity and lung function were measured at the 
start and near the end of the rehabilitation programme, by the same methods as in papers 1 
and 2.
In this paper, exercise capacity values were presented both as unadjusted values (6MWD) in 
meters and as percent of expected values, adjusted for age, gender, weight and height (6MWD 
%) (67).  
Lung function was presented as unadjusted values in litres (FEV1) and as percent of expected 
values, adjusted for age, gender and height (FEV1 %) (62). 
ANOVAs and multiple regression analyses were used to check for gender differences on all 
variables at the different times of measurement. The multiple regression analyses were used in 
order to assess gender differences in exercise capacity and self-reported variables, after 
controlling for differences in lung function, since there was a statistically significant gender 
difference in FEV1 %. Repeated measures ANOVAs were first used to test changes over time 
for the whole sample and secondly for interaction effects gender x time. Gender x time 
ANCOVAs were also conducted with FEV1 % at T1 as a covariate, to test gender differences 
in self-report variables and walking distance while controlling for lung function. Pearson 
correlation coefficients were calculated to test associations between variables.
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Paper 5 
A combined sample of 132 COPD patients – 92 COPD patients and 40 asthma patients – was 
assessed on a set of questionnaire-based indicators immediately before and after the 4 weeks 
pulmonary rehabilitation programme and at six months follow-up.
We measured total scores of disease-specific HS (BPQ), general perceived QoL (PQoL) and 
trait anxiety (STAI). Also, cohabitation status was registered as a dichotomous variable 
defined by asking patients to answer yes or no to the question: “Are you living alone?” These 
scores were used in paper 5.
We used Pearson Chi-square test to check for difference in female percentage and t-test for 
independent samples to analyse age difference between the two diagnostic groups. 
ANCOVAs for repeated measures assessed changes in BPQ, PQoL and STAI for the whole 
sample plus group x time effects. In the group x time analyses for asthma versus COPD 
patients, gender and cohabitation were used as covariates. We also tested whether 
rehabilitation effects were different for patients with different cohabitation status. In these 
analyses, gender and diagnosis were used as covariates. Cohen’s d was used as an estimate of 
effect size (ES).
Additionally, for analyses purposes in this thesis, patients with different cohabitation status 
were also tested for rehabilitation effects on three different PQoL subscores;  PQoL physical 
= mean of items 1, 2, 4, 5 and 19, PQoL social = mean of items 8 –18 and PQoL cognitive = 
mean of items 3 and 6.  
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Results
Paper 1 
The analyses in paper 1 were conducted to investigate whether the BPQ can be used to 
measure not only self-reported HS as a whole, but also two subdimensions – “functional 
status” and  “health-related quality of life” – that had previously been hypothesised in the 
COPD literature (68). Results in paper 1 indicated a two-component solution for the short-
version BPQ, which was consistent with previous data using the longer version (4). In our 
PCA the three first eigenvalues were 3.91, 1.43 and 0.87, and the ten different items of the 
short-version BPQ loaded in a meaningful way on the two components. However, we found 
that self-reported “physical health status” and “emotional health status” would be the most 
appropriate labels to describe what is measured in the two dimensions of the BPQ. Both of the 
BPQ subscores correlated statistically significantly with general perceived QoL, but QoL was 
more closely associated with the emotional subscore than with the physical subscore. As 
expected, physical HS was highly associated with exercise capacity while emotional HS was 
highly associated with emotional stability and happiness. Lung function (FEV1 %) was more 
highly associated with physical HS than with emotional HS, but none of these associations 
were strong.
To check that our interpretations regarding a two-factor solution would be similar across 
factoring methods, we ran exploratory factor analyses with alternative methods for factor 
extractions and rotations in addition to the PCA. Overall, these analyses gave very similar 
results.
For example, a factor analysis with principal axis factoring as extraction method and direct 
oblimin rotation resulted in the pattern matrix (table 1) and the structure matrix (table 2) 
presented below. This analysis indicated a two factor solution with correlated factors, in 
which the two factors correlated 0.48.  SPSS 12.0.1 was used for these analyses. 
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Table 1. Pattern matrix 
 Factors 
 1 2 
Variables   
Speed on the flat (item 1) 0.87  - 0.12 
Distance on the flat (item 2) 0.64  - 0.09 
Bath or shower (item 3) 0.61 0.08 
Light gardening or DIY (item 4) 0.55 0.12 
Family or friends (item 6) 0.42 0.39 
Energy (item 5) 0.37 0.21 
Anxiety (item 10)  - 0.10 0.84 
Depression (item 9) 0.13 0.65 
Sleep (item 8)  - 0.05 0.57 
Social gatherings (item 7) 0.16 0.42 
Table 2. Structure matrix 
 Factors 
 1 2 
Variables   
Speed on the flat (item 1) 0.82 0.30 
Distance on the flat (item 2) 0.60 0.22 
Bath or shower (item 3) 0.65 0.38 
Light gardening or DIY (item 4) 0.61 0.38 
Family or friends (item 6) 0.61 0.59 
Energy (item 5) 0.47 0.39 
Anxiety (item 10) 0.30 0.79 
Depression (item 9) 0.44 0.71 
Sleep (item 8) 0.22 0.54 
Social gatherings (item 7) 0.36 0.49 
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In paper 1 – based on the PCA results – we suggested a simple scoring procedure to calculate 
two subscores of the BPQ:  Adding items 1-4 gives a physical HS subscore and adding items 
7-10 gives an emotional HS subscore. The item scales (0-3) of the BPQ may be considered 
dubious as to having the properties of real interval scales; hence this represents a weakness of 
the study when conducting PCAs and factor analyses with these variables. However, the 
conceptual meaningfulness of item groupings and the associations between the two 
component scores and other variables supported our suggestions and conclusions.
A confirmatory factor analysis (CFA) using AMOS 7.0 showed that our scoring model – with 
items 1-4 loading on a physical factor while items 7-10 loading on an emotional factor – was 
acceptable (the two factors correlated 0.48, uncorrelated error terms for the observed 
variables, chi-square = 26.8, df = 19, p = 0.109, CFI (comparative fit index) = 0.958, RMSEA 
(root mean square error of approximation) = 0.065). CFA also showed that a two-factor model 
with items 1-3 loading on a physical factor while items 8-10 loading on an emotional factor 
might have been an even better solution (chi-square = 7.8, df = 8, p = 0.450, CFI = 1.000, 
RMSEA = 0.000, the two factors correlated 0.45). However, since ours was a small sample in 
CFA terms, and due to the limitations of item scales mentioned above, CFA results should be 
interpreted with caution. 
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Paper 2 
Our main aim in this paper was to investigate to what extent it is meaningful to discriminate 
QoL from the different components of HS. We found that two QoL scales were highly 
correlated (r = 0.73) as were the two HS scales (r = 0.83), but the correlations between HS 
and QoL scales were lower (from r = 0.55 to r = 0.60). The results provided support for the 
assertion that QoL scales and HS scales measure something different and so it is worth 
including both types of scale in outcome assessment. However, when the subscales of the HS 
scales were considered, a somewhat different picture emerged. The PCA (table 3, below), 
supported by the table of correlations between variables (table 4, below), showed that the 
physical problems subscale of the BPQ and the activity subscale of the SGRQ measure the 
same concept, namely the effect of COPD on physical activities, and that these two subscales 
are highly correlated with both exercise capacity and to a lesser extent, lung function. The 
data also indicated that the emotional subscale of the BPQ and the symptoms subscale of the 
SGRQ measure the same latent variable as QoL, and that this latent variable is associated with 
trait emotional stability/neuroticism. As in paper 1, our results indicated that it can be 
important to distinguish two different components of HS, and that these two components have 
different associations to other, physically or emotionally oriented variables. 
Table 3. Rotated matrix from the PCA 
 Components 
 1 2 
Variables   
QOLS tot - 0.82 - 0.20 
BPQ emo   0.80   0.29 
PQoL tot - 0.79 - 0.20 
Neuroticism - 0.74   0.04 
SGRQ symp   0.71   0.20 
SGRQ imp   0.60   0.56 
6 min wd   0.02 - 0.88 
BPQ phys   0.27   0.86 
SGRQ act   0.26   0.79 
Extraction method: Principal components. 
Rotation method: Varimax. 
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Table 4. Correlations coefficients. 
6MWD PQoL QOLS BPQphys 
BPQ
emo 
SGRQ
symp 
SGRQ
act
SGRQ
imp 
Neuroti
cism 
FEV1 %   0.41   0.14   0.15 - 0.34 - 0.24   0.02 - 0.41 - 0.18   0.13 
6MWD    0.17   0.21 - 0.68 - 0.25 - 0.14 - 0.52 - 0.41   0.05 
PQoL 0.73 - 0.36 - 0.62 - 0.54 - 0.37 - 0.49   0.38 
QOLS    - 0.39 - 0.60 - 0.53 - 0.33 - 0.50   0.41 
BPQ phys       0.42   0.36 0.68   0.57 - 0.26 
BPQ emo 0.53   0.38   0.67 - 0.58 
SGRQ symp         0.41   0.48 - 0.41 
SGRQ act 0.54 - 0.21 
SGRQ imp         - 0.42 
Correlation coefficients  0.50 in bold 
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Paper 3 
The first aim in paper 3 was to assess whether physically related variables would improve 
more than emotionally related variables, since the rehabilitation program was focused 
primarily on physical exercise. Results confirmed these expectations (see table 5, below), as 
statistically significant improvements were observed for exercise capacity and for the total 
scores and the physically related subscores of HS and QoL, while no statistically significant 
improvements were observed for the emotional HS component, the social QoL component or 
for trait anxiety. We also observed a statistically significant improvement in lung function for 
the sample, which was unexpected, since other rehabilitation studies do not tend to find such 
effects (16;69). Adjustment of medications and/or better medical compliance might possibly 
be an explanation for the improvements of lung function among patients in our study. 
Table 5. Scores before and after the rehabilitation programme. N = 92 
Variables
Scores before 
rehabilitation: 
Means (SD) 
Scores after 
rehabilitation: 
Means (SD) 
p-values Effect size Cohen’s d 
FEV1 %   50.78   (18.92)   53.23   (19.41) p = 0.001 0.13 
6MWD 500.54 (114.61) 528.42 (123.85) p < 0.001 0.23 
BPQ total    10.83     (5.39)     9.99     (5.71) p = 0.006 0.15 
BPQ phys     4.30     (2.35)     3.88     (2.40) p = 0.001 0.18 
BPQ emo     3.60     (2.49)     3.39     (2.57) p = 0.236 0.08 
PQoL total     5.06     (1.67)     5.36     (1.70) p = 0.014 0.18 
PQoL phys     4.62     (1.94)     5.15     (1.88) p = 0.001 0.28 
PQoL social     5.10     (1.76)     5.31     (1.79) p = 0.072 0.12 
STAI   42.73   (10.77)   42.38   (11.61) p = 0.610 0.03 
The second aim in paper 3 was to assess the relations between changes in different outcome 
variables. We expected that changes in exercise capacity would be related to changes in 
perceived HS and QoL – especially to the physically related subscores. If patients responded 
well to the PRP by increasing their 6 minutes walking distance, this should be reflected by 
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corresponding improvements in physical HS and possibly also in physically related QoL. 
Surprisingly, these expectations were disconfirmed, since longitudinal associations between 
exercise capacity and other outcome variables were missing. While the 6MWD was 
significantly correlated to other variables cross-sectionally, changes in walking distance were 
unrelated to changes in the other outcome variables (see table 6, below). Our results suggest 
that COPD patients do not respond uniformly to a PRP, or to different parts of a PRP. 
Furthermore, they indicate that it is important to use a set of different instruments and tests for 
evaluation purposes, since both subjective and objective improvements can be important for 
the patients.
Table 6. Changes in walking distance related to changes in the other main variables 
Variables
Group 1:
Worsening or 
no improvement 
on the 6MWD 
Group 2: 
Small or 
moderate
improvement 
on the 6MWD 
Group 3: 
Large
improvement 
on the 6MWD 
Group x Time 
  N = 29 N = 32 N = 31 p Value 
BPQ tot  t1    11.8 (5.3)     10.2 (6.2)    10.5 (4.6) p = 0.650 
 t2    10.5 (5.6) 9.5 (6.6)    10.0 (4.9)  
BPQ phys t1 4.7 (2.4) 4.1 (2.5) 4.2 (2.1) p = 0.900 
 t2 4.1 (2.4) 3.7 (2.7) 3.9 (2.1)  
PQoL tot  t1 4.7 (1.6) 5.2 (1.7) 5.2 (1.7) p = 0.586 
 t2 5.2 (1.7) 5.4 (1.9) 5.5 (1.6)  
PQoL phys t1 4.1 (1.9) 4.9 (1.9) 4.9 (1.9) p = 0.507 
 t2 4.8 (1.7) 5.2 (2.2) 5.4 (1.6)  
STAI t1 44.4 (12.2) 42.2 ( 9.5) 41.6 (10.8) p = 0.366 
 t2 44.0 (12.8) 43.1 (12.3) 40.2 ( 9.6)  
FEV1 % t1 51.1 (21.2) 48.7 (16.9) 52.7 (19.0) p = 0.925 
 t2 53.4 (22.2) 50.8 (17.7) 55.6 (18.7)  
Group1: (ǻ6MWD  0 meters), Group 2 : (0 < ǻ6MWD  40 meters), Group 3 : 
(ǻ6MWD > 40 meters).  
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Paper 4 
Paper 4 addressed two central research questions: Did the four weeks PRP have different 
effects for men and women? Were there any differences between female and male COPD 
patients referred to inpatient pulmonary rehabilitation? Additionally, we analyzed associations 
between different outcome measures, which could be important for the interpretation and 
discussion of gender differences, if any such differences were discovered.
Table 7.  Longitudinal Results for Women and Men 
Variables  Mean (SD) Mean (SD) Mean (SD) Gender x Time 
  t1 t2 t3 p Value 
BPQ tot women 10.3 (5.2) 9.4 (5.1) 10.3 (5.7) p = 0.677 
men 10.4 (4.6) 9.6 (5.4) 10.0 (5.8)  
PQoL tot women   5.2 (1.5) 5.3 (1.5)   5.3 (1.4) p = 0.521 
men   5.1 (1.6) 5.5 (1.7)   5.3 (1.7)  
STAI women 44.1 (11.6) 43.5 (11.4) 43.7 (11.5) p = 0.656 
men 41.4 (10.0) 41.3 (10.5) 42.3 (11.1)  
 T1 T2   
6MWD women 506.1 (105.6) 530.1 (122.0)  p = 0.346 
men 509.5 (127.9) 544.0 (131.1)   
6MWD % women 98.1 (19.0) 102.5 (21.3)  p = 0.484 
men 88.6 (22.4)   94.4 (22.5)   
FEV1 women 1.4 (0.4)   1.5 (0.5)  p = 0.773 
men 1.5 (0.7)   1.6 (0.7)   
FEV1 % women 57.9 (17.9)   61.2 (20.1)  p = 0.562 
 men 45.5 (19.0)   47.9 (18.0)   
For 6MWD, N(women) = 41 and N(men) = 40. For FEV1 % and STAI, N(women) = 45 
and N(men) = 46. For all other measures, N = 46 for both genders. 
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The results in table 7 (above) illustrate our findings that female and male COPD patients 
tended to respond similarly to a four weeks inpatient PRP as no significant gender x time 
effect was discovered for any variable, over any period of time, including all subscores on the 
HS and QoL instruments. During their stay at the clinic, both women (p = 0.004, ES = 0.21) 
and men (p < 0.001, ES = 0.26) had statistically significant improvements with moderate 
effect sizes on the 6MWD. In both gender groups, HS scores improved from immediately 
before to immediately after the PRP, but reverted at follow-up. The male group had somewhat 
larger improvements in QoL scores than females immediately after the PRP, but this 
difference was smaller at follow-up. Anxiety scores changed very little; however with no 
substantial gender differences. 
For self-report measures, no statistically significant gender difference in average scores were 
observed for any variable, at any time of measurement with or without controlling for FEV1 
%. Females had statistically significant higher mean FEV1 % than males. 6MWD values were 
similar for the two gender groups. Females had larger 6MWD % values than males, but this 
difference disappeared after controlling for FEV1 %. One odd observation deserves a little 
attention: Both gender groups in our study had mean scores close to 100 on the 6MWD %, 
which was interesting for two reasons. First, COPD patients are not expected to have normal 
values on a walking test (6MWD %) which was standardized for healthy persons (67). 
Secondly, de Torres et al (70) observed the same phenomenon and concluded that there is 
probably a need to develop predictive values for 6MWD in different areas of the world. We 
agree to this.  
Walking distance was highly associated to lung function while QoL (total score PQoL) was 
highly associated to anxiety. HS (total score BPQ) was moderately associated to all the other 
variables. Very low associations were observed between QoL/anxiety versus exercise 
capacity/lung function.
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Paper 5 
In paper 5, we compared our COPD sample to a sample of asthma patients for short and long-
term changes in HS, QoL and anxiety scores after the PRP. The asthma group had 
significantly more females and a lower mean age than the COPD group. 
Asthma and COPD patients had different longitudinal development on HS, while less such 
differences on QoL and trait anxiety levels. The development in scores for the two groups is 
depicted in table 8, below. 
Table 8. Mean scores at t1, t2 and t3 for the COPD (N = 92) and Asthma (N = 40) 
group
Variable Diagnosis t1 t2 t3 Group x Time  
BPQ  COPD 10.3 (4.9) 9.5 (5.2) 10.2 (5.7) 
 Asthma   9.8 (5.0) 9.6 (5.3)   8.7 (5.1) 
p = 0.013 
PQoL  COPD   5.2 (1.5) 5.4 (1.6)   5.3 (1.5) 
 Asthma   5.5 (1.8) 5.8 (1.7)   5.8 (1.8) 
p = 0.491 
STAI COPD 42.8 (10.8) 42.4 (10.9) 43.0 (11.3) 
 Asthma 42.2 (10.8) 40.9 (10.8) 40.2 (11.6) 
p = 0.350 
The COPD group had improved on HS (p = 0.005) and QoL (p = 0.042) scores immediately 
after the PRP but then relapsed at follow-up, while trait anxiety scores changed very little. In 
contrast, the asthma patients had less immediate HS improvement but made progress in the 
follow-up period and actually achieved a significant positive change in BPQ scores from t1 to 
t3 (p = 0.040). Asthma patients also had a somewhat better long-term development than 
COPD patients on QoL and anxiety, but the improvements from t1 to t3 on the PQoL (p = 
0.122) and the STAI (p = 0.134) did not quite reach levels of significance for the asthma 
group. The positive PQoL development from t1 to t2 was significant for the COPD group 
while not for the asthma patients. The reason for this was probably the difference in sample 
sizes; effect sizes in the two groups (COPD = 0.16, asthma = 0.17) were similar. Overall, 
changes in HS, QoL and anxiety for the two groups were not large; effect sizes were small or 
moderate only. 
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An additional finding in this paper was that QoL changes were small for patients living 
together with someone, while patients living alone improved their QoL immediately after the 
PRP and the improvement was sustained in the follow-up period (shown in table 9, below).  
Table 9. Mean PQoL total scores at t1, t2 and t3 for patients living 
alone (N = 35) and patients not living alone (N = 97) 
Cohabitation t1 t2 t3 Group x time 
Alone   4.8 (1.6)   5.4 (1.7)   5.4 (1.7) 
Not alone   5.4 (1.6)   5.6 (1.6)   5.5 (1.6) 
p = 0.039 
For all patients living alone (COPD plus asthma patients), there was a statistically significant 
QoL improvement from before rehabilitation to follow-up six months after the PRP (p = 
0.017), and this tendency existed within both groups of patients since there was no 
statistically significant interaction effect diagnosis x cohabitation x time. Effect sizes for 
PQoL change from t1 to t3 were 0.37 for COPD patients living alone and 0.31 for asthma 
patients living alone, which indicate that these changes tended to be relatively large, at least as 
compared to the other analysed changes in our study.
Analyses performed on subscores of the PQoL showed that the differences in longitudinal 
QoL score development between the two cohabitation groups were mainly due to the PQoL 
social subscores (shown in table 10, below). 
Table 10. Mean PQoL subscores at t1, t2 and t3 for patients living alone  
(N = 35) and patients not living alone (N = 97)
Variable Cohabitation t1 t2 t3 Group x time 
Alone   4.7 (1.8)   5.3 (1.8)   5.3 (1.8) PQoL
social Not alone   5.6 (1.7)   5.6 (1.7)   5.5 (1.7) 
p = 0.007 
Alone   4.8 (1.9)   5.4 (2.0)   5.3 (2.0) PQoL
physical Not alone   4.8 (1.8)   5.3 (1.8)   5.3 (1.9) 
p = 0.704 
Alone   6.0 (2.0)   5.9 (2.2)   6.3 (2.0) PQoL
cognitive Not alone   6.1 (2.3)   6.1 (2.1)   6.1 (2.1) 
p = 0.577 
No statistically significant cohabitation x time effect was observed for HS or trait anxiety. 
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General discussion 
Data from our first sample indicated that it can be important to distinguish two different 
components in a disease-specific health status instrument (BPQ) for pulmonary patients. One 
of these components appears to reflect psychological well-being, whereas the other 
component measures levels of activity and physical performance.
The manifestation of two different HS components illustrates a clinically important feature of 
COPD; an imbalance often exists between physical and emotional manifestations of the 
disease. In the clinic, one sometimes meet patients with severe, disabling COPD who are 
surprisingly calm about their condition – at other times patients who are deeply bothered by 
their breathing problems, however with spirometric values far better than expected from their 
clinical appearance. COPD is a somatic disease, predominantly characterized by a reduction 
of lung function, dyspnoea, lack of energy and an ensuing reduction of physical functioning 
as compared to healthy persons. A physical HS component captures these symptoms. In 
addition to the physical manifestations, COPD samples also tend to score higher than normal 
on negative affect variables such as anxiety and depression (19;71), which is likely to be 
reflected in an emotional HS component. However, in the COPD literature, associations 
between levels of lung function and emotional problems have generally been very low (14;72-
74). Apparently, COPD may have a negative influence on perceived emotional status, but this 
is less obvious than the negative impact COPD has on perceived physical status. While 
perceived physical health status tend to be closely associated with pulmonary function, 
perceived emotional health status obviously depends on a more complex set of psychological, 
social and physiological processes; hence our results were not entirely surprising. However, 
they underscore the importance of evaluating both physical and emotional health status in 
COPD.
In our first sample, subscores of the BPQ and another disease-specific instrument (SGRQ) 
loaded differently on a physical versus an emotional HS component. BPQ physical subscore 
and the activity subscale of the SGRQ loaded on the physical factor. BPQ emotional subscore 
and the symptom subscale of the SGRQ loaded on the emotional factor, consistent with 
research showing that reporting of respiratory symptoms has an emotional basis (75;76). 
However, the impact factor of the SGRQ cross-loaded, showing that items in this subscale 
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were influenced by both latent variables. These results suggested that if the intention is to use 
the total score of an HS scale in addition to a QoL scale, then it makes little difference which 
scale is used. However, if the intention is to use a HS scale only, then the BPQ may be better 
as it provides a clearer separation between the underlying physical problem and the emotional 
latent variable compared with the SGRQ. 
As was shown in paper 2, total scores on the two different HS instruments (BPQ and SGRQ) 
were highly correlated, as were total scores on two different QoL instruments (PQoL and 
QOLS). Correlations between HS and QoL scales were also statistically significant, but 
considerably lower. Thus, to a certain extent, these data supported the assertion that QoL 
scales and HS scales measure something different and so it is worth including both types of 
scale in outcome assessment.  
However, our data also indicated that while physical HS loaded together with exercise 
capacity on a latent variable related to physical functioning, emotional HS loaded together 
with variables such as QoL and emotional stability/neuroticism on a latent variable 
characterised by psychological well-being. On the basis of these results, we stated that an HS 
scale may be adequate as a measure of outcome without the need to introduce a QoL measure, 
so long as the subscales of the HS measures are considered independently.
This statement was contradicted by our subsequent, longitudinal data, since results in paper 3 
– changes in outcome variables from before to after rehabilitation – provided a more 
complicated picture. As expected, the physically related outcome variables generally 
improved more than variables related to well-being and emotional status. Physical HS 
improved more than emotional HS and there was no statistically significant improvement in 
either emotional HS or anxiety after the rehabilitation programme. Still, emotional HS was 
not an adequate outcome measure to replace QoL scores as we postulated in paper 2, since in 
contrast to emotional HS, total scores on the PQoL improved significantly. 
Overall, the observation of statistically significant improvements in exercise capacity, HS 
total scores and QoL total scores – from immediately before to immediately after the PRP – 
was in line with a number of  previous studies (25;28;32;35;46;47;49;51;77-83). Effect sizes 
have varied a lot across such reports; ours were in the middle or lower region. One reason for 
the modest results may be the relatively short duration of the PRP in our study. A recent meta-
analysis of respiratory rehabilitation for COPD patients (84) reported a total of 31 randomised 
controlled trials (RCTs). Four of them were based on inpatient PRPs, with durations of 24, 8, 
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8 and 6 weeks. Only one of the 31 RCTs reported had a program as short as 4 weeks. In the 
light of this, large effect sizes could probably not be expected in our case. 
The fact that we discovered no significant changes in anxiety levels for our sample was in line 
with Engstrøm et al (34) but contrary to the results of Garuti et al (26) who found significant 
reductions of anxiety and depression levels from before to after an inpatient PRP – and 
contrary to Withers et al (85) who observed significant improvements in anxiety and 
depression both immediately after a PRP and at 6 months follow-up. Also, a recent review 
showed that comprehensive PRPs for COPD patients tend to have significantly better short-
term effects than standard care on anxiety and depression levels, although education alone or 
exercise alone had no effect. Two recent studies using cognitive therapy (86) and cognitive 
behavioural therapy (87) showed anxiety reduction among COPD patients. Such elements, 
however, were not systematically included in our PR program.  
One possible reason for the discrepancy between the results mentioned above and ours may 
be the choice of measurement scales; we measured STAI trait anxiety – asking how one 
usually feels – while both Garuti and Withers, for example, used the hospital anxiety and 
depression scale (HADs) which assesses perceptions of anxiety and depression symptoms 
experienced during the last week. Another reason may be that PRPs tend to vary, both in 
content and duration, hence the relatively short duration and the large emphasize on exercise 
and education in our PRP may have made anxiety improvements less likely. Finally, the 
different COPD samples studied will vary as to anxiety levels pre rehabilitation, and the 
likelihood of significant anxiety reductions after a PRP is certainly less in a non-anxious 
sample. However, the average STAI scores in our sample (42.7) before the PRP was relatively 
high – both as compared to scores on reference groups in the STAI manual (66) and to a 
COPD sample (39.4) in a previous study (88) – hence an anxiety reduction after the PRP was 
probably not impossible for our sample. 
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Another interesting result from paper 3 was that when analyses were conducted for subscores 
of the PQoL, we found that a physically related QoL subscore improved more than a social 
QoL subscore – which was much in line with the HS subscores (see table 5). However, when 
running a PCA for the data in paper 3 (see table 11, below) – including the subscores of HS 
and QoL plus anxiety, exercise capacity and lung function – both of the QoL subscores loaded 
highest on the well-being component while the HS subscores split and loaded differently on 
the two components.
Table 11. Rotated matrix from the 
principal component analysis. 
 Components 
 1 2 
Variables   
PQoL social - 0.88   0.18 
STAI   0.87   0.07 
PQoL physical - 0.81   0.20 
BPQ emo   0.75 - 0.33 
6MWD - 0.09   0.88 
FEV1 % - 0.04   0.82 
BPQ phys   0.38 - 0.79 
Extraction method: Principal components 
Rotation method: Varimax. 
 Taken together, results from our two samples showed the importance of assumptions and 
conclusions from cross-sectional data analyses being tested and eventually reconsidered by 
longitudinal results and measurement of change. Two variables with fairly comparable 
loadings on components/factors are not necessarily very highly correlated with each other. 
Also, even in the case when two such variables do correlate highly, their sensitivity to change 
can be different. In our samples, variables such as emotional stability/neuroticism and trait 
anxiety were very likely to have high loadings on a latent variable labelled “well-being”, but 
it may have been too optimistic to expect a significant improvement in e.g. trait anxiety after a 
4 weeks PRP. Both emotional HS (BPQ emo) and general perceived QoL (PQoL total) would 
also be expected to load considerably on the well-being component, but such variables are 
more likely to improve significantly after rehabilitation. Only one of them (PQoL total), 
however, did. 
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We have shown in a previous paper (89) (see figure 1, below) that the largest gaps between 
COPD patients and healthy persons tend to be observed on items related to physical 
functioning. Since PQoL physical scores were lower than PQoL social scores at t1 (table 5)
the potential for improvement may have been somewhat greater for PQoL physical. Also, 
since the PRP had a main focus on physical exercise, it was no surprise that the physical 
subscore showed the largest improvement after rehabilitation.  
Estimated marginal means of the PQoL scores were calculated by using a general linear model with PQoL scores 
as dependent variables, group as fixed factor, and age, gender and personality factors as covariates. 
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A surprising observation, based on results from the sample in paper 3, was the fact that 
changes in exercise capacity was virtually unrelated to changes in HS and QoL – no matter 
whether total scores or subscores were considered. Although some earlier studies have 
reported low or moderate correlation coefficients between changes in exercise tolerance and 
changes in HRQoL (90), our observations were truly surprising; especially as regards the lack 
of correspondence between changes in walking distance and changes in physical HS. In fact, 
the group that worsened or had no improvement on the 6MWD actually showed slightly 
larger improvements on the physical HS scores than the group with large 6MWD 
improvement. Thus, an evaluation of results for a sample of COPD patient after rehabilitation 
can be very different based on whether a self-reported outcome measure or a test of physical 
performance is used. In our case, the patients evidently did not respond uniformly to the 
rehabilitation programme. Some patients managed to increase their exercise capacity 
considerably, while others appeared to think and feel better about their daily functioning or 
general satisfaction with life immediately after the PRP. Again, this shows the importance of 
evaluating both physical and emotional health status in COPD. 
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In paper 4, we compared female and male COPD patients immediately before and 
immediately after the PRP and at follow-up six months later. There was no statistically 
significant gender x time effect for any variable over any period of time; indicating that 
rehabilitation had relatively similar short and long term effects on female and male patients. 
Very few previous studies have tested for gender differences within treatment or rehabilitation 
for COPD patients. In one study (83), only the male COPD group improved on 6MWD, and 
the male group also tended to have the largest HS improvements. Another study (91) reported 
that long-term exercise therapy gave additional benefit in HS scores over short-term therapy, 
but only for males. Hence, although these reports suggested therapeutic interventions to be 
more effective for male than for female COPD patients, our data did not support such a 
conclusion. In fact, our results were more in line with a recent study from Canada (92). 
Although in this sample women improved more than men on one HS subscore (dyspnoea) 
immediately after rehabilitation, overall HS scores and 6MWD scores improved equivalently 
and significantly for both sexes. From a treatment perspective, this should be considered 
satisfactory. On the one hand, it could mean that a structured PRP has the same effects on 
female and male COPD patients. On the other hand, it could indicate that the program was 
flexible enough to suit patients of both sexes.
Additionally, in paper 4, we found that the female group had similar levels of self-reported 
HS, QoL and anxiety as the male group, but better lung function. This could mean that COPD 
hits women harder, which is bad. On the other hand, it could imply that women report more 
symptoms and hence are referred to PRPs at an earlier stage of the disease, which might 
actually be beneficial for the female sex. It has been pointed out that cultural factors may 
influence symptom reporting among COPD patients (93). For example, it may be more 
acceptable for women than for men to report shortness of breath.
It is important, however, to notice the low associations between physical test and self-reported 
variables in this study, which is similar to earlier reports (14;94;95). The correlation 
coefficients clearly indicated independence between “emotional” and “physical” variables. 
Thus, when comparing men and women across such variables, interpretations of results can be 
difficult. For example, since there was little connection between QoL and lung function in the 
sample, the fact that the female group had better lung function but equal QoL to the male 
group does not automatically mean that COPD has greater negative consequences for women. 
Previous studies analyzing gender differences on similar variables (42;96) seem to have 
largely overlooked this problem.  
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In paper 5, we evaluated to what degree the improvement from immediately before to 
immediately after rehabilitation was sustained after six months for the COPD sample, and the 
COPD patients (N = 92) were also compared to a smaller sample of asthma patients (N = 40) 
referred to the same PRP. HS and QoL had improved immediately after rehabilitation for the 
COPD group, but then relapsed at follow-up. Trait anxiety did scores for the sample remained 
stable over time. This development in scores was somewhat in contrast to the results of the 
asthma patients who, overall, had a better long-term development.  
For our COPD sample, a significant positive short-term effect and subsequent relapse of HS 
and QoL scores during the follow-up period was comparable to previous research. In one 
study (97), outcome variables had improved 2 weeks after a PRP but deteriorated during the 
subsequent 6 months; another study found no improvements in HS one year after the 
programme (34). Follow-up regimes may produce better longitudinal results. For example, a 
COPD study with monthly follow-up sessions after the PRP found HS improvements to be 
present after six months but not after one year (46), while a procedure of weekly telephone 
calls and monthly reinforcement visits after rehabilitation produced only modest 
improvements (54). More comprehensive after-care procedures probably produce better 
results, since a weekly community-based maintenance exercise class, combined with a home 
exercise programme, proved to be an effective intervention for long term maintenance of 
improvements in HS and walking distance following pulmonary rehabilitation (98). Also, 
previous studies showing good long-term results after PRPs (49-51) all tended to comprise 
some form of aftercare, and results have even indicated that COPD patients require a 
differentiated aftercare program following rehabilitation (27). Since no systematic after-care 
was applied for our sample of patients, however, it was no great surprise that the COPD group 
had lost their gains in HS and QoL at six months follow-up. 
Our results indicated that a short rehabilitation programme for COPD patients tended to have 
transient effects only, and effective follow-up procedures should be implemented if possible 
since modification of behavioural patterns, coping styles and emotional function probably 
requires longer periods of time for COPD patients (99). However, the best interventions to 
achieve this goal are not known today, and additional research is needed to supply knowledge 
about how different factors can have an impact on long-term results of short-term PRPs (48).  
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There were obvious limitations to our study. The design was quasi-experimental, many 
patients did not want to participate and – as expected – there was a considerable dropout from 
the project since patients were informed that they could withdraw from the study at any time 
without any consequences. Additionally, improvements in scores were only small or 
moderate, as shown by the effect sizes, which also tend to weaken our conclusions. In spite of 
these limitations, the study provided some implications for future studies to explore further. 
A recent qualitative study of  “what really matters” for patients with COPD showed that 
engagement in specific activities and social participation were considered to be of great 
importance (100). Interestingly, an additional observation in our study was that the main part 
of QoL improvements was discovered among patients living alone – a consistent finding in 
both the COPD and asthma sample. Also, on the social subscale of the QoL instrument, 
improvements were observed only for the subsample of patients living alone.
Because of distressing symptoms, pulmonary disease can reduce social activities for patients 
with or without a partner. The negative effect of this on QoL is probably larger among 
patients living alone, an assumption that was supported by the fact that single patients had 
lower average QoL before entering the PRP. A four weeks inpatient PRP may have 
counteracted feelings of isolation and recreated feelings of participation, and our results 
suggest that social sharing can be an important aspect of a PRP. However, there are other 
possible explanations. For example, patients living alone may have been more unconcerned 
about self-care and healthy lifestyle before PRP, making them more receptive for the 
programme interventions. Also, since patients living alone had lower baseline QoL scores, 
there was probably a larger potential for improvement in this group. Nevertheless, a QoL 
improvement sustained over 6 months for this subgroup of patients was a surprising 
observation; hopefully there will be possibilities in the future to further explore the 
importance of social factors for perceived health status and quality of life in pulmonary 
rehabilitation.
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Conclusions
Our results indicated that it is meaningful to use both total scores and subscores of HS and 
QoL instruments to evaluate the impact of COPD on a person’s life and the effects of 
pulmonary rehabilitation. Furthermore, it can be important to distinguish between variables 
related to physical functioning and variables related to psychological well-being. 
A short inpatient PRP was followed by immediate positive changes on HS, QoL and exercise 
capacity for a sample of COPD patients. Significant improvements were observed for 
variables related to physical functioning; emotionally related variables changed considerably 
less, although in a positive direction. The PRP appeared to have similar effects for female and 
male COPD patients. In contrast to an asthma sample, however, most of the gains in HS and 
QoL for the COPD sample had vanished at six months follow-up.
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